A recent New York Times story described a new fad: microdosing GLP-1 anti-obesity drugs like Ozempic, Wegovy, Mounjaro, and Zepbound
It is, however, important to research any interference they may have with your medications
In experiments in mice it has been shown that deletion of CPT-1C results in reduced feeding behavior and lowered body weight similar to studies in which hypothalamic malonyl-CoA levels are elevated
it's well-tolerated and low on the irritation scale
Tirzepatide activates two receptors: GLP-1 and GIP
And that discovery has opened up a whole series of questions about whether these drugs might have effects well beyond blood sugar and body weight, and the pain science community has started paying close attention [1, 9]